Search Results
Sep 03, 2026, 07:00 ET BARTEC Launches New Modular Energy Distribution Panel Series for Hazardous Areas
range from -20°C to +55°C, extendable to -40°C to +55°C with optional heater.Flexible switching and protection options including MCB, RCD and RCBO configurations.Integration of BARTEC ComEx Global control and signaling devices.About BARTECBARTEC
More news about: BARTEC Top Holding GmbH
Sep 03, 2026, 07:00 ET BARTEC Launches New Modular Energy Distribution Panel Series for Hazardous Areas
range from -20°C to +55°C, extendable to -40°C to +55°C with optional heater.Flexible switching and protection options including MCB, RCD and RCBO configurations.Integration of BARTEC ComEx Global control and signaling devices.About BARTECBARTEC
More news about: BARTEC Top Holding GmbH
Aug 27, 2026, 19:11 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Metropolitan Bank Holding Corp.- MCB
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Metropolitan Bank Holding Corp. ("Metropolitan" or the "Company") (NYSE: MCB). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Aug 26, 2026, 13:00 ET MCB Alert: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Metropolitan Bank Holding Corp. (NYSE: MCB) Investors with Significant Losses to Contact Firm
www.hbsslaw.com/cases/metropolitan-bank-holding-corp-mcb-investigation Email: [email protected] Call Direct: 844-916-0895MCB Investigation Focus: Credit Quality
More news about: Hagens Berman Sobol Shapiro LLP
Aug 20, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Metropolitan Bank Holding Corp.- MCB
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Metropolitan Bank Holding Corp. ("Metropolitan" or the "Company") (NYSE: MCB). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Aug 13, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Metropolitan Bank Holding Corp. - MCB
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Metropolitan Bank Holding Corp. ("Metropolitan" or the "Company") (NYSE: MCB). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Aug 06, 2026, 21:58 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Metropolitan Bank Holding Corp.- MCB
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Metropolitan Bank Holding Corp. ("Metropolitan" or the "Company") (NYSE: MCB). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Jul 30, 2026, 10:10 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Metropolitan Bank Holding Corp.- MCB
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Metropolitan Bank Holding Corp. ("Metropolitan" or the "Company") (NYSE: MCB). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Jul 08, 2026, 09:00 ET The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy
Austrianova announced on May 20, 2026 the completion of a Master Cell Bank (MCB) of genetically modified cells that overexpress the alpha-Klotho protein, a major step on the Company's path to clinical trials [1].- The MCB will now undergo comprehensive independent testing by a top-tier,
More news about: USA News Group
May 28, 2026, 09:15 ET Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum
Bio and joint venture partner Austrianova announced the completion of a GMP-grade Master Cell Bank (MCB) of genetically modified cells overexpressing the α-Klotho protein. The MCB will now undergo comprehensive third-party testing to confirm the absence of pathogenic viruses and adventitious
More news about: USA News Group
May 20, 2026, 09:50 ET Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets
trials, the completion of a Master Cell Bank (MCB) of genetically modified cells that overexpress the α-Klotho protein.Now, the MCB will undergo comprehensive testing to confirm the absence of pathogenic viruses, as well as standard assays to verify the MCB is free from adventitious agents such as
More news about: Market News Updates
May 20, 2026, 08:45 ET Avaí Bio and Austrianova Complete GMP Master Cell Bank, Begin Viral Testing for Cell-Based Klotho Anti-Aging Therapy
Now, the MCB will undergo comprehensive testing to confirm the absence of pathogenic viruses, as well as standard assays to verify the MCB is free from adventitious agents such as bacteria, mycoplasma, fungi, and yeast to meet
More news about: Avai Bio, Inc.
May 14, 2026, 11:00 ET From Transformation to Triumph: Monterey County Bank Hits Profitability Milestone
MONTEREY, Calif., May 14, 2026 /PRNewswire/ -- Monterey County Bank (MCB) today announced a major milestone in its post-acquisition transformation, reporting its first profitable quarter since being acquired in August 2024.
More news about: Monterey County Bank
Apr 24, 2026, 11:59 ET AFS Announces Client Award Recipients, Celebrating Excellence, Growth, and Partnership
continue to advance the future of commercial lending.Adoption AwardThe Adoption Award recognizes Metropolitan Commercial Bank (MCB) for demonstrating a strong commitment to transformation through the successful implementation and adoption of AFSVision and the IRIS Reporting module.
More news about: AFS
Apr 06, 2026, 13:10 ET Why Smart Money Is Shifting From Clinical Data to Manufacturing Lines
manufacturing a Master Cell Bank (MCB) of genetically modified cells designed to produce high levels of the α-Klotho protein. Klotho is a naturally occurring molecule that peer-reviewed research
More news about: USA News Group
Mar 27, 2026, 09:15 ET Scalable Biotech Manufacturing Unlocks a $14B Market
drawing growing scientific interest to the protein's therapeutic potential.Think of the MCB as a permanent, lab-grade seed vault from which the company will create a Working Cell Bank, while storing the MCB cells for many years to come. Every vial—filled with millions of cloned cells inside—traces
More news about: USA News Group
Mar 24, 2026, 11:05 ET Anti-Aging Protein Research Takes a Step Forward with Cell Cloning
early-stage milestone alongside joint venture partner Austrianova: beginning the creation of a Master Cell Bank (MCB) of genetically modified cells that overexpress the α-Klotho protein. An MCB is the process of taking a single genetically engineered cell and cloning it into tens of millions of identical
More news about: Equity Insider
Mar 24, 2026, 10:00 ET Advanced Cell-based Therapy Booming the Success for Healthcare Sector
cellular starting material, there is no consistency, no scalability, and no path from laboratory discovery to therapeutic development. A Master Cell Bank (MCB) is the process of taking a single genetically engineered cell and cloning it into tens of millions of identical copies under GMP-compliant conditions.
More news about: USA News Group
Mar 17, 2026, 09:00 ET Apertura Gene Therapy y Viralgen anuncian una colaboración estratégica para la fabricación de TfR1 CapX
materiales de partida esenciales como la creación de bancos de células maestras (MCB) y el suministro de plásmidos, como parte de sus servicios integrados de fabricación de AAV. Actualmente, estas capacidades se utilizan para generar MCB y plásmidos para la colaboración en el proyecto TfR1 CapX."Gracias
More news about: Viralgen
Mar 17, 2026, 09:00 ET Apertura Gene Therapy et Viralgen annoncent une collaboration stratégique pour la fabrication de TfR1 CapX, une capside de nouvelle génération pour les thérapies géniques destinées à traiter les maladies du système nerveux central.
de départ essentiels tels que la création de banques de cellules mères (MCB) et la fourniture de plasmides dans le cadre de ses services intégrés de fabrication d'AAV. Actuellement, ces capacités sont utilisées pour générer des MCB et des plasmides pour le partenariat TfR1 CapX.« Grâce à cette
More news about: Viralgen
Mar 17, 2026, 09:00 ET Apertura Gene Therapy and Viralgen Announce Strategic Collaboration to Manufacture TfR1 CapX, a Next-Generation Capsid for Gene Therapies Designed to Treat Central Nervous System Diseases
successfully deployed across more than 1.500 batches.Viralgen provides CMC services, including essential starting materials such as Master Cell Bank (MCB) creation and plasmid supply as part of its integrated AAV manufacturing services. Currently, these capabilities are utilized to generate MCBs and plasmids
More news about: Viralgen
Mar 17, 2026, 09:00 ET Apertura Gene Therapy and Viralgen Announce Strategic Collaboration to Manufacture TfR1 CapX, a Next-Generation Capsid for Gene Therapies Designed to Treat Central Nervous System Diseases
successfully deployed across more than 1.500 batches.Viralgen provides CMC services, including essential starting materials such as Master Cell Bank (MCB) creation and plasmid supply as part of its integrated AAV manufacturing services. Currently, these capabilities are utilized to generate MCBs and plasmids
More news about: Viralgen
Mar 17, 2026, 09:00 ET Apertura Gene Therapy und Viralgen kündigen strategische Zusammenarbeit zur Herstellung von TfR1 CapX an, einem Kapsid der nächsten Generation für Gentherapien zur Behandlung von Erkrankungen des zentralen Nervensystems
erfolgreich eingesetzt.Viralgen bietet CMC-Dienstleistungen, einschließlich wesentlicher Ausgangsmaterialien wie die Erstellung einer Master Cell Bank (MCB) und die Bereitstellung von Plasmiden als Teil seiner integrierten AAV-Herstellungsdienste. Derzeit werden diese Möglichkeiten genutzt, um MCBs und Plasmide
More news about: Viralgen
Mar 05, 2026, 14:52 ET Herpes Virus Fluidizes Cell Nuclei to Multiply Faster
provided by National Institutes of Health (NIH) grants GM132447, AI176335, AI170583, GM056927, and AI073898; National Science Foundation (NSF) grant MCB-2145083, and the Hypothesis Fund.About NYU Langone HealthNYU Langone Health is a fully integrated health system that consistently achieves
More news about: NYU Langone
Mar 03, 2026, 10:02 ET Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them
announced a production milestone alongside joint venture partner Austrianova, initiating manufacturing of a Master Cell Bank (MCB) of genetically modified cells that overexpress the α-Klotho protein. These cells will enable Klothonova, the parties' joint venture, to advance
More news about: USA News Group